Acessibilidade / Reportar erro

An in silico pipeline to filter the Toxoplasma gondii proteome for proteins that could traffic to the host cell nucleus and influence host cell epigenetic regulation

Abstract

Toxoplasma gondii uses epigenetic mechanisms to regulate both endogenous and host cell gene expression. To identify genes with putative epigenetic functions, we developed an in silico pipeline to interrogate the T. gondii proteome of 8313 proteins. Step 1 employs PredictNLS and NucPred to identify genes predicted to target eukaryotic nuclei. Step 2 uses GOLink to identify proteins of epigenetic function based on Gene Ontology terms. This resulted in 611 putative nuclear localised proteins with predicted epigenetic functions. Step 3 filtered for secretory proteins using SignalP, SecretomeP, and experimental data. This identified 57 of the 611 putative epigenetic proteins as likely to be secreted. The pipeline is freely available online, uses open access tools and software with user-friendly Perl scripts to automate and manage the results, and is readily adaptable to undertake any such in silico search for genes contributing to particular functions.

Toxoplasma gondii; nuclear localisation; epigenetics


Toxoplasma gondii is a ubiquitous eukaryotic parasite associated with congenital or acquired ocular and/or brain lesions. It can influence the host’s transcriptome, including through modulation of the host epigenome ( Leng and Denkers 2009Leng J, Denkers EY. Toxoplasma gondii inhibits covalent modification of histone H3 at the IL-10 promoter in infected macrophages. PLoS ONE. 2009; 4(10): e7589. , Leng et al. 2009Leng J, Butcher BA, Egan CE, Abdallah DS, Denkers EY. Toxoplasma gondii prevents chromatin remodelling initiated by TLR-triggered macrophage activation. J Immunol. 2009; 182(1): 489-97. , Lang et al. 2012Lang C, Hildebrandt A, Brand F, Opitz L, Dihazi H, Luder CG. Impaired chromatin remodelling at STAT1-regulated promoters leads to global unresponsiveness of Toxoplasma gondii -infected macrophages to IFN-gamma. PLoS Pathog. 2012; 8(1): e1002483. ). The ability of infectious disease organisms to modulate the host epigenome is an area of increasing interest, which is likely to underpin development of novel therapeutics ( Vanagas et al. 2012Vanagas L, Jeffers V, Bogado SS, Dalmasso MC, Sullivan Jr WJ, Angel SO. Toxoplasma histone acetylation remodelers as novel drug targets. Expert Rev Anti Infect Ther. 2012; 10(10): 1189-201. , Syn et al. 2016Syn G, Blackwell JM, Jamieson SE. Chapter 19. Epigenetics in infectious diseases. In: JL Garcia-Gimenez, editor. Epigenetic biomarkers and diagnostics. Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney, Tokyo: Elsevier Inc and Academic Press; 2016; p. 377-94. ). Experimental studies of T. gondii have demonstrated the presence of epigenetic machinery, including histone ( Hettmann and Soldati 1999Hettmann C, Soldati D. Cloning and analysis of a Toxoplasma gondii histone acetyltransferase: a novel chromatin remodelling factor in Apicomplexan parasites. Nucleic Acids Res. 1999; 27(22): 4344-52. ) and lysine ( Wang et al. 2014Wang J, Dixon SE, Ting L-M, Liu T-K, Jeffers V, Croken MM, et al. Lysine acetyltransferase GCN5b interacts with AP2 factors and is required for Toxoplasma gondii proliferation. PLoS Pathog. 2014; 10(1): e1003830. ) acetyltransferases, histone deacetylases ( Vanagas et al. 2012Vanagas L, Jeffers V, Bogado SS, Dalmasso MC, Sullivan Jr WJ, Angel SO. Toxoplasma histone acetylation remodelers as novel drug targets. Expert Rev Anti Infect Ther. 2012; 10(10): 1189-201. ), SET domain-containing histone lysine methyltransferases ( Sautel et al. 2007Sautel CF, Cannella D, Bastien O, Kieffer S, Aldebert D, Garin J, et al. SET8-mediated methylations of histone H4 lysine 20 mark silent heterochromatic domains in apicomplexan genomes. Mol Cell Biol. 2007; 27(16): 5711-24. ), SWI/SNF2 proteins capable of influencing gene expression through ATP-dependent nucleosome remodelling ( Sullivan Jr et al. 2003Sullivan Jr WJ, Monroy MA, Bohne W, Nallani KC, Chrivia J, Yaciuk P, et al. Molecular cloning and characterization of an SRCAP chromatin remodelling homologue in Toxoplasma gondii . Parasitol Res. 2003; 90(1): 1-8. ), and two predicted cytosine-5 DNA methyltransferase 2 (DNMT2) homologues ( Wei et al. 2017Wei H, Jiang S, Chen L, He C, Wu S, Peng H. Characterization of cytosine methylation and the DNA methyltransferases of Toxoplasma gondii . Int J Biol Sci. 2017; 13(4): 458-70. ).

Availability of pathogen genome sequences provides the opportunity to undertake a more global approach to identify proteins mediating epigenetic effects, particularly in the context of increasing public domain data and tools that facilitate filtering approaches to identify all genes involved in specific molecular pathways. Here we develop an in silico pipeline to first identify all proteins in the T. gondii genome that can both target to eukaryotic cell nuclei and have putative epigenetic functions, and secondly to filter for those which also have secretory signals that could allow them to exit the parasite and affect the host epigenome directly. The pipeline is freely available (http://bioinformatics.childhealthresearch.org.au/software/nuc_loc/), uses open access tools and software with user-friendly Perl scripts to automate and manage the results, and is readily adaptable to undertake any in silico search for genes contributing to specific functions.

The source data used here was ToxoDB (http://toxodb.org) ( Gajria et al. 2007Gajria B, Bahl A, Brestelli J, Dommer J, Fischer S, Gao X, et al. ToxoDB: an integrated Toxoplasma gondii database resource. Nucleic Acids Res. 2007; 36(Database Issue): D553-D6. ), which incorporates sequence and annotation from GenBank for the three clonal lineages of T. gondii: GT1 (Type I), ME49 (Type II) and VEG (Type III). We exported the T. gondii (ME49 strain) proteome of 8318 proteins. The filtering rationale ( Figure ) aimed to find all proteins predicted to: (i) go to a eukaryotic nucleus; (ii) have an epigenetic function; and (iii) be secreted from the parasite into the host cell. The pipeline and filtering parameters summarised below are described in more detail in the [ Supplementary data IV . Table I summarises the protein numbers from each step of the in silico pipeline. Supplementary data I contains both the raw and summary results arising from running all 8318 T. gondii encoded proteins through all in silico tools.


Bioinformatics pipeline outlining the in silico tools and manual methods used to predict parasite proteins with endogenous and exogenous epigenetic function. Step 1: predicts proteins localised to the nucleus; Step 2: predicts proteins with potential epigenetic function; Step 3: applies a filter to determine potential for epigenetic function in the host versus endogenous epigenetic function.

TABLE I
Summary of proteins filtered through the in silico pipeline. The pipeline was designed to identify a set parasite encoded candidates in the putative secretome that could potentially target the host or parasite nucleus and have domains consistent with an epigenetic function

To predict proteins with the potential to localise to eukaryotic cell nuclei, we first used PredictNLS (version 1.3) ( Cokol et al. 2000Cokol M, Nair R, Rost B. Finding nuclear localization signals. EMBO Rep. 2000; 1(5): 411-5. ) combined with AccPro ( Magnan and Baldi 2014Magnan CN, Baldi P. SSpro/ACCpro 5: almost perfect prediction of protein secondary structure and relative solvent accessibility using profiles, machine learning and structural similarity. Bioinformatics. 2014; 30(18): 2592-7. ) to identify proteins containing an exposed putative nuclear localisation signal (NLS), and calculated the overall percentage of exposed residues for each NLS motif. Some proteins, whilst not themselves containing an NLS, gain access to the nucleus when bound to an NLS-containing protein. Proteins may also contain novel NLSs. To capture proteins such as these we used NucPred (version 1.1), a tool that predicts whether or not proteins spend time in the nucleus ( Brameier et al. 2007Brameier M, Krings A, MacCallum RM. NucPred - Predicting nuclear localization of proteins. Bioinformatics. 2007; 23(9): 1159-60. ). Of the 8318 T. gondii encoded proteins extracted from ToxoDB, 3408 were predicted to have the potential to localise to a eukaryotic nucleus. This included 1399 proteins that contain a putative functional exposed NLS motif, as predicted by PredictNLS/ACCpro, and 3201 proteins predicted to spend some time in the nucleus by NucPred. There was an overlap of 1192 proteins. The 2009 proteins predicted to be nuclear localised by NucPred alone could contain as yet unidentified NLSs or be chaperoned into the nucleus.

To predict proteins with an epigenetic function we used InterProScan Version 5 ( Zdobnov and Apweiler 2001Zdobnov EM, Apweiler R. InterProScan - an integration platform for the signature-recognition methods in InterPro. Bioinformatics. 2001; 17(9): 847-8. ), a tool that allows users to query protein sequences against the InterPro database ( Hunter et al. 2012Hunter S, Jones P, Mitchell A, Apweiler R, Attwood TK, Bateman A, et al. InterPro in 2011: new developments in the family and domain prediction database. Nucleic Acids Res. 2012; 40(Database Issue): D306-D12. ). InterProScan predicts structural motifs and domains and provides any available associated Gene Ontology (GO) terms. We also exported a list of manually annotated and predicted GO terms from ToxoDB (version 8.0) for all T. gondii proteins. To allow inference of epigenetic function from GO terms across the orthogonal sub-ontologies (“Cellular Component”, “Molecular Function” and “Biological Process”) we used GOLink ( Francis 2013Francis RW. GOLink: finding cooccurring terms across gene ontology namespaces. Int J Genomics. 2013; 2013: 594528. ), a tool that collates terms across all sub-ontologies that co-occur with a term of interest across the entire GO database. We used GOLink to compile “terms lists” linked to the query terms “regulation of gene expression, epigenetic’’ (GO:0040029) and “histone modification” (GO:0016570). We removed the generic GO term “Protein binding” from both lists to reduce false positives. The two GOLink terms lists used in this process can be found at Supplementary data II . All associated GO terms for each protein were then matched to the top 5% of terms from each of the generated GOLink “terms lists” to determine those parasite proteins predicted to have an epigenetic function. The terms within the 95th percentile were selected as they represent the terms most confidently associated with the initial query terms. Of the 3408 proteins with a prediction of nuclear localisation, 1487 had associated GO terms. The GOLink terms lists ( Supplementary data II ) obtained for “regulation of gene expression, epigenetic” and “histone modification” contained 140 and 168 terms respectively (representing the top 5% of all candidate terms returned by GOLink) with an overlap of 68 terms, leaving 240 unique terms that were used in the matching process. Filtering of these 1487 proteins using our GOLink terms lists resulted in 611 proteins ( Supplementary data III ) that were deemed to be associated with epigenetic functions.

To identify T. gondii encoded proteins that may play a role in modulating the host cell epigenome we used SignalP (version 4.1) to predict proteins with an N-terminal signal peptide (SP) for secretion via the classical secretory pathway. We used the Eukaryote organism groups for our predictions and default D-cutoff values of 0.45 for the SignalP-noTM networks and 0.50 for SignalP-TM networks. Any proteins with a D-score exceeding the relevant cutoff were deemed as having a signal peptide and were included in a putative parasite secretome. As Eukaryotic proteins can be secreted without a classical N-terminal signal peptide, we also used SecretomeP (version 2.0) ( Bendtsen et al. 2004Bendtsen JD, Jensen LJ, Blom N, Von Heijne G, Brunak S. Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng Des Sel. 2004; 17(4): 349-56. ) to predict T. gondii proteins likely to be secreted via a non-classical secretory pathway. This tool is used in conjunction with SignalP: any protein predicted by both SecretomeP and SignalP is likely to be classically secreted, prediction by SecretomeP only suggests a non-classical mechanism. Proteins with a SecretomeP NN-score >0.9 ( Bendtsen et al. 2004Bendtsen JD, Jensen LJ, Blom N, Von Heijne G, Brunak S. Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng Des Sel. 2004; 17(4): 349-56. ) were included in the putative parasite secretome. Of the 611 T. gondii proteins with a predicted epigenetic function, 23 were predicted to be secreted via the classical pathway and 1 via the non-classical pathway.

We noted that GRA10 (TGME49_268900) previously shown ( Ahn et al. 2007Ahn H-J, Kim S, Nam H-W. Nucleolar translocalization of GRA10 of Toxoplasma gondii transfectionally expressed in HeLa cells. Korean J Parasitol. 2007; 45(3): 165-74. ) to be secreted from T. gondii into the host cell and targeted to the host cell nucleus was not predicted to be secreted by either SignalP or SecretomeP. This suggests alternative mechanisms for T. gondii proteins to be secreted, for example, the recently reported ( Coffey et al. 2015Coffey MJ, Sleebs BE, Uboldi AD, Garnham A, Franco M, Marino ND, et al. An aspartyl protease defines a novel pathway for export of Toxoplasma proteins into the host cell. Elife. 2015; 4: pii: e10809. ) aspartyl pathway. To address this, the 587 epigenetic candidates with no prediction of secretion by either SignalP or SecretomeP were further screened to determine if any had been proposed to be secreted through experimental studies, in particular the published experimental secretome ( Zhou et al. 2005Zhou XW, Kafsack BF, Cole RN, Beckett P, Shen RF, Carruthers VB. The opportunistic pathogen Toxoplasma gondii deploys a diverse legion of invasion and survival proteins. J Biol Chem. 2005; 280(40): 34233-44. ). This yielded an additional 33 epigenetic candidates that were deemed secreted. One caveat in using this experimental secretome data was the observation ( Zhou et al. 2005Zhou XW, Kafsack BF, Cole RN, Beckett P, Shen RF, Carruthers VB. The opportunistic pathogen Toxoplasma gondii deploys a diverse legion of invasion and survival proteins. J Biol Chem. 2005; 280(40): 34233-44. ) that a number of cytosolic proteins identified in the secretome could be contaminants due to inadvertent lysis of the parasites during sample preparation. However, since there was no way of distinguishing such false positives from true secreted proteins that might carry novel, possibly T. gondii -specific ( Coffey et al. 2015Coffey MJ, Sleebs BE, Uboldi AD, Garnham A, Franco M, Marino ND, et al. An aspartyl protease defines a novel pathway for export of Toxoplasma proteins into the host cell. Elife. 2015; 4: pii: e10809. ), secretory signals we retained the full list of proteins from the experimental secretome in our gene list. This included retaining all proteins that had at least one peptide from the mass spectrometry analysis that mapped to the T. gondii database, since there was high probability given the experimental conditions that all peptides identified with a high confidence spectral match to the T. gondii genome were of parasite origin. A second caveat was that the experimental secretome contained very few dense granule and no rhoptry proteins, most likely due to the use of 1% ethanol to stimulate parasite secretion ( Zhou et al. 2005Zhou XW, Kafsack BF, Cole RN, Beckett P, Shen RF, Carruthers VB. The opportunistic pathogen Toxoplasma gondii deploys a diverse legion of invasion and survival proteins. J Biol Chem. 2005; 280(40): 34233-44. ). In view of this, the putative secretome list was extended through a search of ToxoDB using keywords such as “Rhoptry”, “Dense Granule” and “Microneme”.

Overall, 57 proteins were predicted to be secreted and have an epigenetic function ( Table II ). These proteins represent 0.7% of the total T. gondii proteome and are considered candidates for translocation to the host cell nucleus during infection with a potential role in the manipulation of the host epigenome. The 554 epigenetic candidates not predicted to be secreted were considered to have an endogenous role in the epigenetic regulation of T. gondii.

TABLE II
Proteins from our pipeline with a potential epigenetic function in modulating the host epigenome. The list is annotated for proteins identified from the in silico secretome, the experimental secretome data, or both

To date, six T. gondii secreted proteins have been experimentally shown to target the host cell nucleus. Rhoptry kinase family proteins 16 (ROP16) ( Saeij et al. 2007Saeij JPJ, Coller S, Boyle JP, Jerome ME, White MW, Boothroyd JC. Toxoplasma co-opts host gene expression by injection of a polymorphic kinase homologue. Nature. 2007; 445(7125): 324-7. ) and 47 (ROP47) ( Camejo et al. 2014Camejo A, Gold DA, Lu D, McFetridge K, Julien L, Yang N, et al. Identification of three novel Toxoplasma gondii rhoptry proteins. Int J Parasitol. 2014; 44(2): 147-60. ), protein phosphatase 2C (PP2C-hn) ( Gilbert et al. 2007Gilbert LA, Ravindran S, Turetzky JM, Boothroyd JC, Bradley PJ. Toxoplasma gondii targets a protein phosphatase 2C to the nuclei of infected host cells. Eukaryot Cell. 2007; 6(1): 73-83. ), and dense granular proteins 10 (GRA10) ( Ahn et al. 2007Ahn H-J, Kim S, Nam H-W. Nucleolar translocalization of GRA10 of Toxoplasma gondii transfectionally expressed in HeLa cells. Korean J Parasitol. 2007; 45(3): 165-74. ), 16 (GRA16) ( Bougdour et al. 2013Bougdour A, Durandau E, Brenier-Pinchart M-P, Ortet P, Barakat M, Kieffer S, et al. Host cell subversion by Toxoplasma GRA16, an exported dense granule protein that targets the host cell nucleus and alters gene expression. Cell Host Microbe. 2013; 13(4): 489-500. ) and 24 (GRA24) ( Braun et al. 2013Braun L, Brenier-Pinchart M-P, Yogavel M, Curt-Varesano A, Curt-Bertini R-L, Hussain T, et al. A Toxoplasma dense granule protein, GRA24, modulates the early immune response to infection by promoting a direct and sustained host p38 MAPK activation. J Exp Med. 2013; 210(10): 2071-86. ). In addition, we report three proteins that have domains associated with histone modifications: TGME49_207080 (TgMYST-B), which contains a histone acetyltransferase domain; TGME49_202490 containing a histone methylation SET domain; and TGME49_210310 which is predicted to have a histone methylation DOT1 domain. It was previously thought that T. gondii did not possess any DOT1 domain histone methyltransferases ( Sullivan Jr and Hakimi 2006Sullivan Jr WJ, Hakimi M-A. Histone mediated gene activation in Toxoplasma gondii . Mol Biochem Parasitol. 2006; 148(2): 109-16. ) but prediction of functional domains using InterProScan now highlights TGME49_210310 as containing a DOT1 domain. The orthologue of TGME49_210310 in the VEG strain of T. gondii (TGVEG_210310) is also annotated as having a DOT1 domain in ToxoDB, adding confidence to our prediction of this DOT1 domain in TGME49_210310. Our in silico analysis also identified one protein involved in nucleosome remodelling, TGME49_278440, which contains a SWI/SNF2 related bromodomain. SWI/SNF members are capable of ATP-dependent destabilisation of histone-DNA interactions. Finally, we report TGME49_228120, currently annotated in ToxoDB as having a “replication foci targeting sequence” of the type uniquely found in the N-terminal region of DNMT1 molecules ( Subramaniam et al. 2014Subramaniam D, Thombre R, Dhar A, Anant S. DNA methyltransferases: a novel target for prevention and therapy. Front Oncol. 2014; 4: 80. ). T. gondii lacks detectable methylcytosine in its DNA ( Gissot et al. 2008Gissot M, Choi S-W, Thompson RF, Greally JM, Kim K. Toxoplasma gondii and Cryptosporidium parvum lack detectable DNA cytosine methylation. Eukaryot Cell. 2008; 7(3): 537-40. ), and has no full-length DNMT1 homologues. The C-terminal 500 amino acid catalytic portion of DNMTs are conserved between C5 DNMTs of eukaryotes and prokaryotic organisms, and harbour the active centre of the enzyme containing amino acid motifs characteristic of the cytosine-C5-methyltransferase. The N-terminal region of DNMT1 molecules carries 3 sequences, including the replication foci targeting sequence, that increase the precision in copying methylation patterns after DNA replication. As this replication foci targeting sequence is unique to DNMT1 molecules, this suggests that TGME49_228120 may represent the remnants of a T. gondii DNMT1 gene.

Overall this in silico analysis has identified several highly interesting candidates for ongoing functional investigations into how T. gondii manipulates host cell processes, specifically via the disruption or modulation of the host epigenome. Recently, it has been proposed that distribution of secretory pathogenesis determinants (genes encoding secretory proteins found in MIC, DG, ROP and SRS superfamilies) within the T. gondii genome is strain-specific ( Lorenzi et al. 2016Lorenzi H, Khan A, Behnke MS, Namasivayam S, Swapna LS, Hadjithomas M, et al. Local admixture of amplified and diversified secreted pathogenesis determinants shapes mosaic Toxoplasma gondii genomes. Nat Commun. 2016; 7: 10147. ). Since we have only analysed the ME49 (Type II) proteome, the proteomes of other T. gondii strains can be analysed using our freely available pipeline to identify strain-specific proteins that may affect host epigenetics. With the discovery of compounds which act against parasites by inhibiting histone deacetylase ( Vanagas et al. 2012Vanagas L, Jeffers V, Bogado SS, Dalmasso MC, Sullivan Jr WJ, Angel SO. Toxoplasma histone acetylation remodelers as novel drug targets. Expert Rev Anti Infect Ther. 2012; 10(10): 1189-201. ), there is increasing interest in identifying the parasite proteins involved in epigenetic regulation, both endogenously and within the host. These proteins represent potential novel drug targets for suppression or treatment of toxoplasmosis.

REFERENCES

  • Ahn H-J, Kim S, Nam H-W. Nucleolar translocalization of GRA10 of Toxoplasma gondii transfectionally expressed in HeLa cells. Korean J Parasitol. 2007; 45(3): 165-74.
  • Bendtsen JD, Jensen LJ, Blom N, Von Heijne G, Brunak S. Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng Des Sel. 2004; 17(4): 349-56.
  • Bougdour A, Durandau E, Brenier-Pinchart M-P, Ortet P, Barakat M, Kieffer S, et al. Host cell subversion by Toxoplasma GRA16, an exported dense granule protein that targets the host cell nucleus and alters gene expression. Cell Host Microbe. 2013; 13(4): 489-500.
  • Brameier M, Krings A, MacCallum RM. NucPred - Predicting nuclear localization of proteins. Bioinformatics. 2007; 23(9): 1159-60.
  • Braun L, Brenier-Pinchart M-P, Yogavel M, Curt-Varesano A, Curt-Bertini R-L, Hussain T, et al. A Toxoplasma dense granule protein, GRA24, modulates the early immune response to infection by promoting a direct and sustained host p38 MAPK activation. J Exp Med. 2013; 210(10): 2071-86.
  • Camejo A, Gold DA, Lu D, McFetridge K, Julien L, Yang N, et al. Identification of three novel Toxoplasma gondii rhoptry proteins. Int J Parasitol. 2014; 44(2): 147-60.
  • Coffey MJ, Sleebs BE, Uboldi AD, Garnham A, Franco M, Marino ND, et al. An aspartyl protease defines a novel pathway for export of Toxoplasma proteins into the host cell. Elife. 2015; 4: pii: e10809.
  • Cokol M, Nair R, Rost B. Finding nuclear localization signals. EMBO Rep. 2000; 1(5): 411-5.
  • Francis RW. GOLink: finding cooccurring terms across gene ontology namespaces. Int J Genomics. 2013; 2013: 594528.
  • Gajria B, Bahl A, Brestelli J, Dommer J, Fischer S, Gao X, et al. ToxoDB: an integrated Toxoplasma gondii database resource. Nucleic Acids Res. 2007; 36(Database Issue): D553-D6.
  • Gilbert LA, Ravindran S, Turetzky JM, Boothroyd JC, Bradley PJ. Toxoplasma gondii targets a protein phosphatase 2C to the nuclei of infected host cells. Eukaryot Cell. 2007; 6(1): 73-83.
  • Gissot M, Choi S-W, Thompson RF, Greally JM, Kim K. Toxoplasma gondii and Cryptosporidium parvum lack detectable DNA cytosine methylation. Eukaryot Cell. 2008; 7(3): 537-40.
  • Hettmann C, Soldati D. Cloning and analysis of a Toxoplasma gondii histone acetyltransferase: a novel chromatin remodelling factor in Apicomplexan parasites. Nucleic Acids Res. 1999; 27(22): 4344-52.
  • Hunter S, Jones P, Mitchell A, Apweiler R, Attwood TK, Bateman A, et al. InterPro in 2011: new developments in the family and domain prediction database. Nucleic Acids Res. 2012; 40(Database Issue): D306-D12.
  • Lang C, Hildebrandt A, Brand F, Opitz L, Dihazi H, Luder CG. Impaired chromatin remodelling at STAT1-regulated promoters leads to global unresponsiveness of Toxoplasma gondii -infected macrophages to IFN-gamma. PLoS Pathog. 2012; 8(1): e1002483.
  • Leng J, Butcher BA, Egan CE, Abdallah DS, Denkers EY. Toxoplasma gondii prevents chromatin remodelling initiated by TLR-triggered macrophage activation. J Immunol. 2009; 182(1): 489-97.
  • Leng J, Denkers EY. Toxoplasma gondii inhibits covalent modification of histone H3 at the IL-10 promoter in infected macrophages. PLoS ONE. 2009; 4(10): e7589.
  • Lorenzi H, Khan A, Behnke MS, Namasivayam S, Swapna LS, Hadjithomas M, et al. Local admixture of amplified and diversified secreted pathogenesis determinants shapes mosaic Toxoplasma gondii genomes. Nat Commun. 2016; 7: 10147.
  • Magnan CN, Baldi P. SSpro/ACCpro 5: almost perfect prediction of protein secondary structure and relative solvent accessibility using profiles, machine learning and structural similarity. Bioinformatics. 2014; 30(18): 2592-7.
  • Saeij JPJ, Coller S, Boyle JP, Jerome ME, White MW, Boothroyd JC. Toxoplasma co-opts host gene expression by injection of a polymorphic kinase homologue. Nature. 2007; 445(7125): 324-7.
  • Sautel CF, Cannella D, Bastien O, Kieffer S, Aldebert D, Garin J, et al. SET8-mediated methylations of histone H4 lysine 20 mark silent heterochromatic domains in apicomplexan genomes. Mol Cell Biol. 2007; 27(16): 5711-24.
  • Subramaniam D, Thombre R, Dhar A, Anant S. DNA methyltransferases: a novel target for prevention and therapy. Front Oncol. 2014; 4: 80.
  • Sullivan Jr WJ, Hakimi M-A. Histone mediated gene activation in Toxoplasma gondii . Mol Biochem Parasitol. 2006; 148(2): 109-16.
  • Sullivan Jr WJ, Monroy MA, Bohne W, Nallani KC, Chrivia J, Yaciuk P, et al. Molecular cloning and characterization of an SRCAP chromatin remodelling homologue in Toxoplasma gondii . Parasitol Res. 2003; 90(1): 1-8.
  • Syn G, Blackwell JM, Jamieson SE. Chapter 19. Epigenetics in infectious diseases. In: JL Garcia-Gimenez, editor. Epigenetic biomarkers and diagnostics. Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney, Tokyo: Elsevier Inc and Academic Press; 2016; p. 377-94.
  • Vanagas L, Jeffers V, Bogado SS, Dalmasso MC, Sullivan Jr WJ, Angel SO. Toxoplasma histone acetylation remodelers as novel drug targets. Expert Rev Anti Infect Ther. 2012; 10(10): 1189-201.
  • Wang J, Dixon SE, Ting L-M, Liu T-K, Jeffers V, Croken MM, et al. Lysine acetyltransferase GCN5b interacts with AP2 factors and is required for Toxoplasma gondii proliferation. PLoS Pathog. 2014; 10(1): e1003830.
  • Wei H, Jiang S, Chen L, He C, Wu S, Peng H. Characterization of cytosine methylation and the DNA methyltransferases of Toxoplasma gondii . Int J Biol Sci. 2017; 13(4): 458-70.
  • Zdobnov EM, Apweiler R. InterProScan - an integration platform for the signature-recognition methods in InterPro. Bioinformatics. 2001; 17(9): 847-8.
  • Zhou XW, Kafsack BF, Cole RN, Beckett P, Shen RF, Carruthers VB. The opportunistic pathogen Toxoplasma gondii deploys a diverse legion of invasion and survival proteins. J Biol Chem. 2005; 280(40): 34233-44.
  • Financial support: RWF was supported by the Australian Medical Bioinformatics Resource (AMBeR) Project under an NHMRC-funded Multi-institutional Agreement (Project ID 404025), the WA State Government Centres of Excellence Program, and the McCusker Charitable Foundation. GS was supported by an Australian Postgraduate Award and the Stan and Jean Perron Top-Up Award.

Publication Dates

  • Publication in this collection
    2018

History

  • Received
    31 Oct 2017
  • Accepted
    17 Apr 2018
Instituto Oswaldo Cruz, Ministério da Saúde Av. Brasil, 4365 - Pavilhão Mourisco, Manguinhos, 21040-900 Rio de Janeiro RJ Brazil, Tel.: (55 21) 2562-1222, Fax: (55 21) 2562 1220 - Rio de Janeiro - RJ - Brazil
E-mail: memorias@fiocruz.br